⚠ COVID-19 INFORMATION: Resources, Vaccine Information

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19) (CARAVAN)

Official Title: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19) (CARAVAN)

The primary objectives of this study are to evaluate the safety, tolerability, and pharmacokinetics (PK) of remdesivir (RDV) in participants with laboratory-confirmed coronavirus disease 2019 (COVID-19) aged 0 days to < 18 years.

ClinicalTrials.gov ID: NCT04431453

Principal Investigator: Muller, William J., MD, PhD

Study Type: Interventional

Currently Recruiting Patients: Yes

Contact Information:

Laura Fearn, RN

Research Nurse

312.227.6285